Tecentriq
Tecentriq
$10,000.00
Tecentriq (atezolizumab; Roche/Chugai) is an antibody designed to target programmed death-ligand 1 (PD-L1) on tumor cells, allowing the body’s immune system to recognize and properly respond to the tumor.
Publisher: Datamonitor Healthcare
- Description
- Contents
Drug Overview
Tecentriq (atezolizumab; Roche/Chugai) is a fully humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1). PD-L1 is expressed on the surface of antigen-presenting cells and some tumor cells. PD-L1 binds to programmed death-1 (PD-1) co-inhibitory receptors which are expressed on the surface of T cells after T-cell activation. The receptor ligand interaction produces inhibitory signals which regulate T-cell activation and promote immune tolerance, which favors tumor progression. By blocking the PD-L1/PD-1 interaction, Tecentriq enables T-cell activation and allows the immune system to mount a more effective anti-tumor response.
CONTENTS
5 OVERVIEW
5 Drug Overview
6 Product Profiles
6 Tecentriq : Non-small cell lung cancer (NSCLC)
24 Tecentriq : Melanoma
37 Tecentriq : Prostate cancer
48 Tecentriq : Colorectal cancer (CRC)
62 Tecentriq : Ovarian cancer
72 Tecentriq : Bladder cancer
84 Tecentriq : Renal cell cancer (RCC)
91 atezolizumab : Breast cancer: triple-negative
LIST OF FIGURES
15 Figure 8: Abraxane sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
16 Figure 8: Alecensa for non-small cell lung cancer – SWOT analysis
17 Figure 10: Datamonitor Healthcare’s drug assessment summary for Alecensa in non-small cell lung cancer
19 Figure 11: Alecensa sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
30 Figure 34: Datamonitor Healthcare’s drug assessment summary for Iressa in non-small cell lung cancer
31 Figure 35: Datamonitor Healthcare’s drug assessment summary for Iressa in non-small cell lung cancer
40 Figure 53: Datamonitor Healthcare’s drug assessment summary for Tarceva in non-small cell lung cancer
41 Figure 54: Datamonitor Healthcare’s drug assessment summary for Tarceva in non-small cell lung cancer
42 Figure 39: Keytruda sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
53 Figure 57: Datamonitor Healthcare’s drug assessment summary for Tecentriq in non-small cell lung cancer
54 Figure 16: Datamonitor Healthcare’s drug assessment summary for Avastin in non-small cell lung cancer
55 Figure 41: Datamonitor Healthcare’s drug assessment summary for Mekinist in non-small cell lung cancer
57 Figure 42: Mekinist sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
68 Figure 43: Datamonitor Healthcare’s drug assessment summary for Opdivo in non-small cell lung cancer
69 Figure 44: Datamonitor Healthcare’s drug assessment summary for Opdivo in non-small cell lung cancer
80 Figure 19: Cyramza for non-small cell lung cancer – SWOT analysis
87 Figure 48: Datamonitor Healthcare’s drug assessment summary for Portrazza in non-small cell lung cancer
88 Figure 49: Portrazza sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
89 Figure 63: Xalkori sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
97 Figure 50: Datamonitor Healthcare’s drug assessment summary for Tafinlar in non-small cell lung cancer
98 Figure 51: Tafinlar sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
6 Table 1: Tecentriq drug profile
8 Table 2: Tecentriq pivotal trial data in non-small cell lung cancer
13 Table 3: Tecentriq ongoing late-phase trial data in non-small cell lung cancer
20 Table 4: Tecentriq sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
22 Table 5: Tecentriq patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
25 Table 6: Tecentriq drug profile
26 Table 7: Tecentriq ongoing late-phase trials in melanoma
28 Table 8: Tecentriq early-phase data in melanoma
34 Table 9: Tecentriq sales for melanoma across the US and five major EU markets, by country ($m), 2017–26
36 Table 10: Tecentriq patient numbers for melanoma across the US and five major EU markets, by country, 2017–26
37 Table 81: Tarceva late-phase trial data in non-small cell lung cancer
39 Table 12: Tecentriq Phase III trials in prostate cancer
45 Table 13: Tecentriq sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
48 Table 59: Mekinist and Tafinlar pivotal trial data in non-small cell lung cancer
50 Table 15: Tecentriq Phase III trial in colorectal cancer
52 Table 16: Tecentriq early-phase data in colorectal cancer
58 Table 17: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
60 Table 18: Patients treated with Tecentriq in the US and five major EU markets, by country, 2016–25
63 Table 19: Tecentriq drug profile
64 Table 20: Tecentriq Phase III trials in ovarian cancer
66 Table 21: Overview of Phase I data for Tecentriq in ovarian cancer
73 Table 22: Tecentriq drug profile
75 Table 23: Tecentriq pivotal trial data in urothelial bladder cancer
76 Table 24: Tecentriq ongoing late-phase trials in urothelial bladder cancer
85 Table 25: Tecentriq drug profile
86 Table 26: Tecentriq Phase III trial in renal cell cancer
92 Table 27: Atezolizumab drug profile
93 Table 28: Atezolizumab Phase III trial in triple-negative breast cancer
94 Table 29: Atezolizumab Phase Ib data in triple-negative breast cancer
95 Table 30: Atezolizumab Phase I data in triple-negative breast cancer
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
